Researchers, led by Dr. Bing Wang, Professor in the Department of General Surgery at Shanghai Ninth People's Hospital and Shanghai Jiao Tong University School of Medicine in Shanghai, China, are utilizing mesenchymal stem cells (MSCs) to treat obesity and type II diabetes, two of the biggest healthcare concerns [change to ‘most significant healthcare concerns and maintain the link] for adults worldwide. This study explored the use of MSCs (the same type of stem cells found in teeth) to treat the inflammation due to obesity that often causes or exacerbates the insulin resistance in type II diabetes. In an animal model, the stem cells were used to to restore metabolic balance and mitigate insulin resistance that arises when high blood glucose levels persist for extended periods of time. The stem cells, known for their anti-inflammatory properties, also expressed a growth factor called neuregulin 4, which is known to effectively combat the effects of obesity.
Researchers at the Harvard University’s Stem Cell Institute have engineered stem cells to become insulin producing cells, potentially providing an important source of pancreatic cells for the development of more effective treatment alternatives for millions of diabetics around the world. The technique increased insulin-producing cell yield from 30% to 80% by targeting the production of a specific protein utilized by insulin-producing beta cells. This enabled the researchers to concentrate the stem cells and yield more beta cells that can then be transplanted into diabetic individuals. Additionally, the concentration of cells should allow researchers to use smaller and less invasive devices to deliver the therapeutic cells in clinically relevant numbers.
Mesenchymal stem cells (MSCs) have been found to be effective in accelerating healing time for diabetics. In patients with diabetes, high blood sugar levels negatively impact circulation and impair the immune system’s ability to fight off infections at the site of wounds. In an animal study, adipose derived MSCs, proved to be effective at decreasing inflammation and increasing circulation around wounds. Previous studies have utilized MSCs recovered from bone marrow. This study demonstrates the potential of MSCs, which can be derived from multiple sources, including teeth, to treat the millions of diabetics around the world who suffer from this debilitating affliction.
Researchers at Cornell University are working on a stem cell-infused implant that could cure insulin deficiency for diabetics. Type I diabetes results from inadequate or malfunctioning insulin-producing beta cells in the islets of the pancreas, as well as an autoimmune response that attacks the body's insulin-producing cells. This treatment utilizes stem cells and directs them to differentiate into these cells. As opposed to daily insulin injections, the treatment is designed to provide a long-term solution that eliminates the need to constantly monitor blood sugar. It utilizes a naturally derived hydrogel to create a thread packed with stem cells induced to become pancreatic islets which is then implanted into the abdomen. Additionally, the treatment addresses what no other current treatment addresses: the body’s immune system attacking the insulin-producing cells. Encasing the cells protects them from the autoimmune response, increasing their efficacy and lifespan.
In several clinical and animal studies, researchers are utilizing mesenchymal stem cells (MSCs) to treat Type II Diabetes Mellitus (T2DM). Type 2 Diabetes affects approximately 415 million people worldwide, with diabetes mellitus (DM) further exacerbating diabetes’ adverse health effects. Symptoms of DM are caused by both a lack of insulin, as-well-as an intolerance to the scarce amount of insulin that is produced by the pancreatic islet cells. DM is typically a precursor to ischemic heart disease, stroke, blindness and chronic kidney disease with no effective treatments currently available to prevent these complications. With previous treatments using donated organs and insulin producing cells proving unsuccessful, MSCs are emerging as an extremely effective tool to restore normal function to the pancreatic islet cells and alleviate the other symptoms of DM. MSCs (the same type of stem cells that are found in teeth) not only normalize natural insulin levels, but also help ameliorate insulin resistance in the body’s tissues by creating a favorable microenvironment.